AbCellera

AbCellera presented phase‑II results for the NK3R antibody ABCL635 at a healthcare conference showing about a twofold greater reduction in moderate to severe hot flashes versus approved small‑molecule therapies, with 37% of patients experiencing complete absence of hot flashes after a single dose. The safety profile has been unremarkable so far, notably without signs of elevated liver enzymes, and the company sees a potential multi‑billion‑dollar market for vasomotor symptoms. AbCellera plans to complete the ongoing phase‑II, hold discussions with regulators and start a pivotal phase‑III study in the second half of 2025; additional candidates and follow‑on programs are intended to supplement the pipeline. » More on de.investing.com

Abcellera Biologics shares rose to a 52-week high of $12.15 and are up about 172.5% year-to-date. Despite the rally, InvestingPro rates the stock as overvalued and the RSI indicates an overbought territory. In Q2 the company missed expectations with an adjusted loss of $0.18 per share and revenue of $4.1 million, but highlighted a strong cash position and announced a guaranteed public offering of $200 million. Positive top-line results from the Phase 2 study of ABCL635 prompted Truist to raise its price target from $12 to $30 while keeping a "Buy" rating. » More on de.investing.com

Abcellera Biologics shares climbed to a 52-week high of $11.51 after gaining 148% over the past year and 259% in the past six months. An InvestingPro analysis classifies the stock as overvalued and points to an overbought condition based on the RSI. In Q2 the company reported an adjusted loss of $0.18 per share and revenue of $4.1 million, both below analysts' expectations. AbCellera announced a guaranteed public offering of $200 million and simultaneously reported positive Phase‑2 results for ABCL635, after which Truist significantly raised its price target. » More on de.investing.com